基础医学与临床 ›› 2014, Vol. 34 ›› Issue (3): 418-421.
• 短篇综述 • 上一篇 下一篇
邹彬镔,石庆之
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
Received:
Revised:
Online:
Published:
摘要: Carfilzomib为2代蛋白酶体抑制剂,近期已用于复发/难治多发性骨髓瘤(RRMM)的治疗。该药对硼替佐米耐药和未接受过硼替佐米治疗的患者都有较好疗效,且不良反应可耐受。与一代蛋白酶体抑制剂硼替佐米比较,Carfilzomib引起的外周神经病变少见。
关键词: Carfilzomib, 蛋白酶体抑制剂, 多发性骨髓瘤, 复发, 难治, 抗骨髓瘤
Abstract: Carfilzomib is a second-generation selective proteasome inhibitor that has been recently used for relapse or refractory multiple myeloma(RRMM). It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.
Key words: Carfilzomib, proteasome inhibitor, multiple myeloma, relapse, refractory, anti-myeloma
邹彬镔 石庆之. Carfilzomib治疗复发/难治多发性骨髓瘤的临床进展[J]. 基础医学与临床, 2014, 34(3): 418-421.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2014/V34/I3/418